CN107496452A - Biocolloid dispersant and preparation method thereof - Google Patents
Biocolloid dispersant and preparation method thereof Download PDFInfo
- Publication number
- CN107496452A CN107496452A CN201710890392.7A CN201710890392A CN107496452A CN 107496452 A CN107496452 A CN 107496452A CN 201710890392 A CN201710890392 A CN 201710890392A CN 107496452 A CN107496452 A CN 107496452A
- Authority
- CN
- China
- Prior art keywords
- added
- biocolloid
- silver nitrate
- obtains
- pure water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
A kind of biocolloid dispersant and preparation method thereof, step：Silver nitrate crystal is added in pure water and stirred evenly, obtains silver nitrate crystal solution；Glycerine is added in pure water and stirred evenly, obtains dilute glycerite；Menthol is added in pure water and stirred evenly, obtains menthol solutions；Dilute glycerite is stirred evenly with menthol solutions, obtains mixed liquor；Silver nitrate crystal solution is stirred evenly with mixed liquor, obtains silver nitrate crystal solution mixed liquor；Ternary acid is added in silver nitrate crystal solution mixed liquor and carries out acidification, obtains silver nitrate crystal solution mixed liquor；Tartaric acid is added in pure water and stirred evenly, obtains tartaric acid solution；Tartaric acid solution is added in silver nitrate crystal solution mixed liquor and stirred evenly, obtains stand-by liquid；Sodium alginate is added in pure water and dissolves by heating and stirs, bleeding agent stirring is added, obtains stabilizer；Stand-by liquid is added in the stirring container for fill pure water and stirred, stabilizer is added and continues to stir, successively through standing, filtering and filling, obtain finished product.
Description
Technical field
The present invention relates to a kind of biocolloid dispersant, suitable for the various organization surface of a wound, prevention, control trauma surface infestation, promotees
Enter wound healing, and further relate to the preparation method of the biocolloid dispersant, belong to medical surgery medication and its technology of preparing
Field.
Background technology
Both at home and abroad it is generally acknowledged to such as burn, scald and the situation of the open surface of a wound etc caused by surface of a wound sense
Dye medication is mainly sulfadiazine silver cream (also referred to as " sulphadiazine ointment ") or suspension, and its active ingredient is main in addition to sulphadiazine
If silver ion, the medicine is widely used in clinic.
" Wound-protection liquid and preparation method thereof " that invention patent mandate notification number CN100560057C recommends objectively indicates
Above-mentioned sulfadiazine silver cream is existing to be short of and compensate for its shortcoming.The formula of the patent is：Wrapped in per 1000g finished product liquors
Contain：Silver ion powder 0.16-0.36g, gelatin 0.1-0.4g, ternary acid (phosphoric acid or citric acid) 0.5-1g, bleeding agent (peroxidating
Hydrogen) 12-14.3g, tartaric acid 0.4-0.8g, remaining is pure water.The technique effect of four aspects of the CN100560057C can be found in
Its row of Instructions Page 3 the 12nd to 17.
Application for a patent for invention publication No. CN102218079A (shield wound biocolloid dispersant and preparation method thereof) analysis
Shortcoming existing for foregoing CN100560057C and the formula for proposing the property improved, the finished product shield wound per 1000g weight are biological
Contain in colloidal dispersant：Silver ion powder 0.12-0.4g, sodium alginate 0.06-0.44g, ternary acid (phosphoric acid or citric acid)
0.5-1g, bleeding agent (hydrogen peroxide) 14.5-16g, tartaric acid 0.4-0.8g, remaining is pure water.The CN102218079A is by marine alga
Sour sodium instead of the gelatin that the Dependent Animals in CN100560057C formula obtain, therefore with preferable security, stability
And the feature of environmental protection, and also there is good penetrability, wound healing time is short, will not develop immunity to drugs, free from extraneous odour and isometric without sensitization
Place.
However, the product obtained by above-mentioned two patent formulas is found in medicinal use：In debridement performance, alleviate
Wound pain and healing speed aspects are not enough to the desired logical disadvantage for reaching expectation, it is therefore necessary to improved,
Technical scheme described below is caused under this background.
The content of the invention
The task of the present invention, which is to provide, a kind of to be helped to guarantee safety and the feature of environmental protection, is advantageous to embody good stabilization
Property, be beneficial to improve debridement performance, have the biocolloid dispersant be easy to pain of alleviation and accelerate healing speed.
The present invention another task be to provide a kind of preparation method of biocolloid dispersant, this method preparation condition is not
It is harsh and industrial amplification production requirement can be met and the technique effect of biocolloid dispersant made from ensureing
Embodied comprehensively.
To embody the top priority for completing the present invention, technical scheme provided by the invention is：A kind of biocolloid dispersant,
It is characterised by including in the refined biometric colloidal dispersant of every 1000g weight：Silver nitrate crystal 0.01-0.45g, sodium alginate
0.005-0.009g, ternary acid 0.1-0.4g, tartaric acid 0.4-0.8g, glycerine 0.1-0.4g, menthol 0.5-1g and bleeding agent
10-13g, remaining is pure water.
In the specific embodiment of the present invention, described ternary acid is phosphoric acid or citric acid.
In another specific embodiment of the present invention, described tartaric acid is the tartaric acid of SILVER REAGENT.
In another specific embodiment of the present invention, described bleeding agent is hydrogen peroxide.
In another specific embodiment of the present invention, described pure water is deionized water or distilled water.
In the also specific embodiment of the present invention, the purity of the deionized water and distilled water is 0.1-0.16
μs/cm。
To embody another task for completing the present invention, technical scheme provided by the invention is：A kind of biocolloid dispersant
Preparation method, comprise the following steps：
A) silver nitrate crystal 0.01-0.45g is added in pure water and stirred evenly, obtains silver nitrate crystal solution；
B) glycerine 0.1-0.4g is added in pure water and stirred evenly, obtains dilute glycerite；
C) menthol 0.5-1g is added in pure water and stirred evenly, obtains menthol solutions；
D) by by step B) obtained dilute glycerite with by step C) obtained menthol solutions stir evenly, are mixed
Liquid；
E) by by step A) obtained silver nitrate crystal solution with by step D) obtained mixed liquor stirs evenly, obtain silver nitrate
Crystalloid solution mixed liquor；
F) ternary acid 0.1-0.4g is added to by step E) it is acidified in obtained silver nitrate crystal solution mixed liquor
Handle and adjust pH value, obtain the silver nitrate crystal solution mixed liquor of acidification；
G) tartaric acid 0.4-0.8g is added in pure water and stirred evenly, obtains tartaric acid solution；
H) by by step G) obtained tartaric acid solution is added to by step F) the obtained silver nitrate crystal of acidification
Stirred evenly in solution mixed liquor, obtain stand-by liquid；
I) sodium alginate 0.005-0.009g is added in pure water and dissolves by heating and stirs, adds bleeding agent 10-13g
Stirring, obtains stabilizer；
J) by by step H) obtained stand-by liquid is added to filling pure water and stirred in the stirring container equipped with agitator
Mix, then add by step G) obtained stabilizer continues to stir and adjust pH value, then successively through standing, filtering and fill
Dress, obtains 1000g biocolloid dispersants.
In a still more specific embodiment of the invention, step F) described in time of acidification be 10-
30min, described regulation pH value is that pH value is adjusted into 1.5-2.
The present invention's and then in a specific embodiment, step I) described in the temperature that heats be 45-65 DEG C；Step
J the adjustment pH value described in) is that pH value is adjusted into 3-4.
Step J in yet a further embodiment of the present invention) described in time of standing be 50-
70min, it is described to be filtered into the filtering of 100 mesh filter screens；Step A) to E) and G) to H) described in time for stirring evenly be 10-20min；Step
Rapid I) and step J) described in time for stirring be 20-30min.
One of technique effect of technical scheme provided by the invention, due to having used sodium alginate in formula, thus have
There are security, stability and the feature of environmental protection；Two, used bleeding agent due to being selected in formula, thus debridement performance can be improved；It
Three, menthol has been used due to being selected in formula, thus both there is preferable refrigerant effect, again with pain of alleviation well；It
Four, due to having selected glycerine in formula, thus there is excellent moistening effect, wetting action is played for Wound healing environment,
It is advantageous to accelerate the healing rate to the wound after debridement.
Embodiment
Embodiment 1：
A) 0.45g is analyzed and stirred evenly in the silver nitrate crystal addition 15g deionized waters of pure level, obtains 15.45g silver nitrates crystalline substance
Liquid solution；
B) 0.25g glycerine is added in 12g distilled water and stirred evenly, obtains the dilute glycerites of 12.25g；
C) 1g menthols are added in 15g distilled water and stirred evenly, obtain 16g menthol solutions；
D) by by step B) obtained dilute glycerites of 12.25g with by step C) obtained 16g menthol solutions stir evenly,
Obtain 28.25g mixed liquors；
E) by by step A) obtained 15.45g silver nitrate crystals solution with by step D) obtained 28.25g mixed liquors stir
It is even, obtain 43.70g silver nitrate crystal solution mixed liquors；
F) 0.1g phosphoric acid is added to by step E) it is acidified in obtained 43.70g silver nitrate crystal solution mixed liquors
30min is handled, and adjusts pH value to 2, obtains the 43.80g silver nitrate crystal solution mixed liquors of acidification；
G) 0.6g tartaric acid is added in 10g deionized waters and stirred evenly, obtains 10.6g tartaric acid solutions；
H) by by step G) obtained 10.6g tartaric acid solutions are added to by step F) the obtained 43.80g of acidification
Stirred evenly in silver nitrate crystal solution mixed liquor, obtain the stand-by liquid of 54.40g；
I) 0.009g sodium alginates are added to dissolve and stir in the case where heating-up temperature is 45 DEG C in 8g distillations and (stirred molten
Solution), the stirring of 13g hydrogen peroxide is added, obtains 21.009g stabilizers；
J) by by step H) the obtained stand-by liquid of 54.40g be added to fill 924.591g deionized waters and equipped with stirring
Mix and stirred in the stirring container of device, then added by step I) obtained 21.009g stabilizers continue to stir and adjust pH value
To 4, then 1000g biocolloid dispersants are obtained through standing 70min, 100 mesh filter screens filtering and filling successively.
The step A of the present embodiment) to E) and G) to H) described in time for stirring evenly be respectively 20min；Step I) and step J)
Described in time for stirring be respectively 25min.
Embodiment 2：
A) 0.01g is analyzed and stirred evenly in the silver nitrate crystal addition 12g distilled water of pure level, obtains 12.01g silver nitrate crystals
Solution；
B) 0.1g glycerine is added in 10g deionized waters and stirred evenly, obtains the dilute glycerites of 10.1g；
C) 0.5g menthols are added in 18g distilled water and stirred evenly, obtain 18.5g menthol solutions；
D) by by step B) obtained dilute glycerites of 10.1g with by step C) obtained 18.5g menthol solutions stir evenly,
Obtain 28.6g mixed liquors；
E) by by step A) obtained 12.01g silver nitrate crystals solution with by step D) obtained 28.6g mixed liquors stir
It is even, obtain 40.61g silver nitrate crystal solution mixed liquors；
F) 0.25g phosphoric acid is added to by step E) it is acidified in obtained 40.61g silver nitrate crystal solution mixed liquors
20min is handled, and adjusts pH value to 1.5, obtains the 40.86g silver nitrate crystal solution mixed liquors of acidification；
G) 0.4g tartaric acid is added in 12g deionized waters and stirred evenly, obtains 12.4g tartaric acid solutions；
H) by by step G) obtained 12.4g tartaric acid solutions are added to by step F) the obtained 40.86g of acidification
Stirred evenly in silver nitrate crystal solution mixed liquor, obtain the stand-by liquid of 53.26g；
I) 0.007g sodium alginates are added in 9g distilled water to dissolve and stir in the case where heating-up temperature is 65 DEG C and (stirred
Dissolving), the stirring of 10g hydrogen peroxide is added, obtains 19.007g stabilizers；
J) by by step H) the obtained stand-by liquid of 53.26g be added to fill 927.733g distilled water and equipped with stirring
Stirring, then added by step I in the stirring container of device) obtained 19.007g stabilizers continue to stir and adjust pH value extremely
3.5, then successively through stand 50min, 100 mesh filter screens filtering and it is filling, obtain 1000g biocolloid dispersants.
The step A of the present embodiment) to E) and G) to H) described in time for stirring evenly be respectively 10min；Step I) and step J)
Described in time for stirring be respectively 30min.
Embodiment 3：
A) 0.23g is analyzed and stirred evenly in the silver nitrate crystal addition 10g distilled water of pure level, obtains 10.23g silver nitrate crystals
Solution；
B) 0.4g glycerine is added in 15g deionized waters and stirred evenly, obtains the dilute glycerites of 15.4g；
C) 0.7g menthols are added in 20g deionized waters and stirred evenly, obtain 20.7g menthol solutions；
D) by by step B) obtained dilute glycerites of 15.4g with by step C) obtained 20.7g menthol solutions stir evenly,
Obtain 36.1g mixed liquors；
E) by by step A) obtained 10.23g silver nitrate crystals solution with by step D) obtained 36.1g mixed liquors stir
It is even, obtain 46.33g silver nitrate crystal solution mixed liquors；
F) 0.4g citric acids are added to by step E) acid is carried out in obtained 46.33g silver nitrate crystal solution mixed liquors
Change processing 10min, and adjust pH value to 1.8, obtain the 46.73g silver nitrate crystal solution mixed liquors of acidification；
G) 0.8g tartaric acid is added in 15g deionized waters and stirred evenly, obtains 15.8g tartaric acid solutions；
H) by by step G) obtained 15.8g tartaric acid solutions are added to by step F) the obtained 46.73g of acidification
Stirred evenly in silver nitrate crystal solution mixed liquor, obtain the stand-by liquid of 62.53g；
I) 0.005g sodium alginates are added in 10g deionized waters and dissolves and stirs (i.e. in the case where heating-up temperature is 55 DEG C
Stirring and dissolving), the stirring of 11.5g hydrogen peroxide is added, obtains 21.505g stabilizers；
J) by by step H) the obtained stand-by liquid of 62.53g be added to fill 915.965g deionized waters and equipped with stirring
Mix and stirred in the stirring container of device, then added by step I) obtained 21.505g stabilizers continue to stir and adjust pH value
To 3, then 1000g biocolloid dispersants are obtained through standing 60min, 100 mesh filter screens filtering and filling successively.
The step A of the present embodiment) to E) and G) to H) described in time for stirring evenly be respectively 15min；Step I) and step J)
Described in time for stirring be respectively 20min.
The purity of deionized water and distilled water described in above-described embodiment 1 to 3 is 0.1-0.16 μ s/cm.
The Specifications of the biocolloid dispersant obtained as above-described embodiment 1 to 3 are as shown in table 1 below to table 4：
Table 1：To radiodermatitis patient outcomes' contrast table
As can be seen from the above table, relative to physiological saline, using the obvious effective rate of biocolloid dispersant of the present invention up to 91%
More than, wound healing time significantly shortens, and invalid example is not present.
Table 2：To severe perianal abscess aftertreatment Contrast on effect table
Two groups of patients underwent's normal surgicals treatment in table 2, although healing number and significant figure and total significant figure are equal simultaneously
And there is no invalid number, but the healing time shortening more notable than control group of the biocolloid dispersant of the present invention.
Table 3：To wound Wound treating healing time contrast table
Note：Compare between two groups,*P ＜ 0.05
Table 4：Wound healing time and pain positive events
In table 4, the surface of a wound is used at flamazine early stage using normal i.e. conventional processing mode, control group
Reason.
In addition, biocolloid dispersant provided by the invention has excellent moistening effect, and removal biology can be played
The effect of film, toxic side effect are lower.There is the healing environment of moistening using biocolloid dispersant of the present invention and debridement can be accelerated
Wound healing time afterwards.
Menthol in biocolloid dispersant of the present invention is making in medicine or pharmacologically excitants, acts on skin
Skin or mucous membrane, there is refrigerant itching-relieving action.
The present invention biocolloid dispersant be used for low level anal fistula postoperative care of patients wound healing time (26.3 ±
2.9)d；Prior art carries out wound healing time (29.0 ± 4.0) d of postoperative care using Iodophor.
The present invention biocolloid dispersant in outpatient service minor operation (head, four limbs superficial tylectomy etc.) to the surface of a wound at
Surface of a wound the average healing after reason is (12.2 ± 4.6) d；When prior art carries out the wound healing of Wound treatment using Iodophor
Between be then (14.6 ± 5.1) d.
The present invention biocolloid dispersant to facial superficial second degree burn patient carry out Wound treatment after wound healing when
Between be (7.6 ± 2.3) d, and utilize physiological saline be (11.2 ± 3.7) d to the wound healing time after Wound treatment.
In summary, technical scheme provided by the invention overcomes the deficiency in prior art, satisfactorily completes invention
Task, the technique effect referred in the superincumbent technique effect column of applicant is objectively cashed.
Claims (10)
1. a kind of biocolloid dispersant, it is characterised in that included in the refined biometric colloidal dispersant of every 1000g weight：Nitre
The silver-colored crystal 0.01-0.45g of acid, sodium alginate 0.005-0.009g, ternary acid 0.1-0.4g, tartaric acid 0.4-0.8g, glycerine
0.1-0.4g, menthol 0.5-1g and bleeding agent 10-13g, remaining is pure water.
2. biocolloid dispersant according to claim 1, it is characterised in that described ternary acid is phosphoric acid or citric acid.
3. biocolloid dispersant according to claim 1, it is characterised in that described tartaric acid is the winestone of SILVER REAGENT
Acid.
4. biocolloid dispersant according to claim 1, it is characterised in that described bleeding agent is hydrogen peroxide.
5. biocolloid dispersant according to claim 1, it is characterised in that described pure water is deionized water or distillation
Water.
6. biocolloid dispersant according to claim 5, it is characterised in that the deionized water and the purity of distilled water
For 0.1-0.16 μ s/cm.
7. a kind of preparation method of biocolloid dispersant as claimed in claim 1, it is characterised in that comprise the following steps：
A) silver nitrate crystal 0.01-0.45g is added in pure water and stirred evenly, obtains silver nitrate crystal solution；
B) glycerine 0.1-0.4g is added in pure water and stirred evenly, obtains dilute glycerite；
C) menthol 0.5-1g is added in pure water and stirred evenly, obtains menthol solutions；
D) will be by step B）Obtained dilute glycerite with by step C）Obtained menthol solutions stir evenly, and obtain mixed liquor；
E) will be by step A）Obtained silver nitrate crystal solution with by step D）Obtained mixed liquor stirs evenly, and obtains silver nitrate crystal
Solution mixed liquor；
F) ternary acid 0.1-0.4g is added to by step E）Acidification is carried out in obtained silver nitrate crystal solution mixed liquor
And pH value is adjusted, obtain the silver nitrate crystal solution mixed liquor of acidification；
G) tartaric acid 0.4-0.8g is added in pure water and stirred evenly, obtains tartaric acid solution；
H) will be by step G）Obtained tartaric acid solution is added to by step F）The silver nitrate crystal solution of obtained acidification
Stirred evenly in mixed liquor, obtain stand-by liquid；
I) sodium alginate 0.005-0.009g is added in pure water and dissolves by heating and stirs, bleeding agent 10-13g is added and stirs
Mix, obtain stabilizer；
J) will be by step H）Obtained stand-by liquid be added to fill pure water and equipped with agitator stirring container in stir, and
Adding afterwards by step G) obtained stabilizer continues to stir and adjust pH value, then obtained successively through standing, filtering and filling
1000g biocolloid dispersants.
8. the preparation method of biocolloid dispersant according to claim 7, it is characterised in that step F）Described in acid
The time for changing processing is 10-30min, and described regulation pH value is that pH value is adjusted into 1.5-2.
9. the preparation method of biocolloid dispersant according to claim 7, it is characterised in that step I) described in heat
Temperature be 45-65 DEG C；Step J）Described in adjustment pH value be that pH value is adjusted to 3-4.
10. the preparation method of biocolloid dispersant according to claim 7, it is characterised in that step J) described in it is quiet
The time put is 50-70min, described to be filtered into the filtering of 100 mesh filter screens；Step A) to E) and G) to H) described in time for stirring evenly
For 10-20min；Step I) and step J) described in time for stirring be 20-30min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710890392.7A CN107496452A (en) | 2017-09-27 | 2017-09-27 | Biocolloid dispersant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710890392.7A CN107496452A (en) | 2017-09-27 | 2017-09-27 | Biocolloid dispersant and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107496452A true CN107496452A (en) | 2017-12-22 |
Family
ID=60699763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710890392.7A Pending CN107496452A (en) | 2017-09-27 | 2017-09-27 | Biocolloid dispersant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496452A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218079A (en) * | 2011-06-02 | 2011-10-19 | 苏州汇涵医用科技发展有限公司 | Biological colloid dispersant used for wound-protection and its preparation method |
| CN104274490A (en) * | 2009-02-11 | 2015-01-14 | 雷蒙特亚特特拉维夫大学有限公司 | Antiseptic compositions comprising silver ions and menthol and uses thereof |
-
2017
- 2017-09-27 CN CN201710890392.7A patent/CN107496452A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274490A (en) * | 2009-02-11 | 2015-01-14 | 雷蒙特亚特特拉维夫大学有限公司 | Antiseptic compositions comprising silver ions and menthol and uses thereof |
| CN102218079A (en) * | 2011-06-02 | 2011-10-19 | 苏州汇涵医用科技发展有限公司 | Biological colloid dispersant used for wound-protection and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104224829A (en) | Injection containing sodium, potassium, magnesium, calcium and glucose injection and preparation method of injection | |
| JP2018530596A (en) | Long term use of zirconium silicate composition and method of use thereof | |
| CN107496452A (en) | Biocolloid dispersant and preparation method thereof | |
| US2530480A (en) | Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same | |
| CN112741803A (en) | Phloroglucinol injection and preparation method thereof | |
| CN108191888A (en) | A kind of 1,4- sulphur azatropylidene medicinal compounds nursed for skin ulcer and its preparation method and application | |
| CN1245161A (en) | Process for preparing chromium L-threonate, its preparing process and application | |
| CN108329334A (en) | A kind of pyrazolo [1,5-a] pyridines drug molecule and its preparation method and application for skin ulcer nursing | |
| CN106074366B (en) | The injection and preparation method thereof for treating the disturbance of consciousness after brain trauma and brain surgery | |
| CN111603479A (en) | Blood purification concentrate | |
| CN115811988A (en) | Blood purification molecule concentrate and preparation method and application thereof | |
| CN106955291B (en) | A kind of antibacterial anti-inflammatory medicament and preparation method thereof | |
| CN102218079A (en) | Biological colloid dispersant used for wound-protection and its preparation method | |
| CN111297891A (en) | A method and composition for preventing and treating vaginal pruritus | |
| CN108478664A (en) | A kind of compound skin rehabilitation ointment and preparation method thereof | |
| CN108096368A (en) | A kind of antibacterial cream of skin for treating recalcitrant dermal disease and preparation method thereof | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| CN113995716A (en) | Medical skin dressing | |
| CN102846661B (en) | Compound nano-silver emulsifiable paste and preparation method thereof | |
| WO2015172607A1 (en) | Yunnan baiyao nanoemulsion and preparation method | |
| CN103561735A (en) | Medicinal preparation ''RENESSANS'' having an antibacterial, anti-ulcerous and immuno-modulating action | |
| CN106668062A (en) | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage | |
| CN1468600A (en) | Prepn process of glucose injection of Doxofylline | |
| Friend | Iron ascorbate in the treatment of anemia | |
| CN108261467A (en) | A kind of skin bacteriostatic gel for treating recalcitrant dermal disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171222 |
|
| WD01 | Invention patent application deemed withdrawn after publication |